LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS.

    Silva, Gabriel A

    BMC neuroscience

    2008  Volume 9 Suppl 3, Page(s) S4

    Abstract: ... such as genes, oligonucleotides, and contrast agents across the blood brain barrier (BBB). The BBB protects and ... delivery and use of drugs and other molecules to the CNS, and as such have a unique advantage over ... isolates CNS structures (i.e. the brain and spinal cord) from the rest of the body, and creates a unique ...

    Abstract Nanotechnologies are materials and devices that have a functional organization in at least one dimension on the nanometer (one billionth of a meter) scale, ranging from a few to about 100 nanometers. Nanoengineered materials and devices aimed at biologic applications and medicine in general, and neuroscience in particular, are designed fundamentally to interface and interact with cells and their tissues at the molecular level. One particularly important area of nanotechnology application to the central nervous system (CNS) is the development of technologies and approaches for delivering drugs and other small molecules such as genes, oligonucleotides, and contrast agents across the blood brain barrier (BBB). The BBB protects and isolates CNS structures (i.e. the brain and spinal cord) from the rest of the body, and creates a unique biochemical and immunological environment. Clinically, there are a number of scenarios where drugs or other small molecules need to gain access to the CNS following systemic administration, which necessitates being able to cross the BBB. Nanotechnologies can potentially be designed to carry out multiple specific functions at once or in a predefined sequence, an important requirement for the clinically successful delivery and use of drugs and other molecules to the CNS, and as such have a unique advantage over other complimentary technologies and methods. This brief review introduces emerging work in this area and summarizes a number of example applications to CNS cancers, gene therapy, and analgesia.
    MeSH term(s) Animals ; Blood-Brain Barrier/metabolism ; Central Nervous System Agents/administration & dosage ; Central Nervous System Agents/pharmacokinetics ; Central Nervous System Agents/therapeutic use ; Central Nervous System Diseases/drug therapy ; Central Nervous System Diseases/metabolism ; Drug Delivery Systems/instrumentation ; Drug Delivery Systems/methods ; Humans ; Nanoparticles/administration & dosage ; Nanotechnology/instrumentation ; Nanotechnology/methods ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/metabolism ; Pharmacokinetics
    Chemical Substances Central Nervous System Agents ; Pharmaceutical Preparations
    Language English
    Publishing date 2008-12-10
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ISSN 1471-2202
    ISSN (online) 1471-2202
    DOI 10.1186/1471-2202-9-S3-S4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS

    Silva Gabriel A

    BMC Neuroscience, Vol 9, Iss Suppl 3, p S

    2008  Volume 4

    Abstract: ... CNS) is the development of technologies and approaches for delivering drugs and other small molecules ... such as genes, oligonucleotides, and contrast agents across the blood brain barrier (BBB). The BBB protects and ... delivery and use of drugs and other molecules to the CNS, and as such have a unique advantage over ...

    Abstract Abstract Nanotechnologies are materials and devices that have a functional organization in at least one dimension on the nanometer (one billionth of a meter) scale, ranging from a few to about 100 nanometers. Nanoengineered materials and devices aimed at biologic applications and medicine in general, and neuroscience in particular, are designed fundamentally to interface and interact with cells and their tissues at the molecular level. One particularly important area of nanotechnology application to the central nervous system (CNS) is the development of technologies and approaches for delivering drugs and other small molecules such as genes, oligonucleotides, and contrast agents across the blood brain barrier (BBB). The BBB protects and isolates CNS structures (i.e. the brain and spinal cord) from the rest of the body, and creates a unique biochemical and immunological environment. Clinically, there are a number of scenarios where drugs or other small molecules need to gain access to the CNS following systemic administration, which necessitates being able to cross the BBB. Nanotechnologies can potentially be designed to carry out multiple specific functions at once or in a predefined sequence, an important requirement for the clinically successful delivery and use of drugs and other molecules to the CNS, and as such have a unique advantage over other complimentary technologies and methods. This brief review introduces emerging work in this area and summarizes a number of example applications to CNS cancers, gene therapy, and analgesia.
    Keywords Neurosciences. Biological psychiatry. Neuropsychiatry ; RC321-571 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Neurology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 612
    Language English
    Publishing date 2008-12-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases.

    Martinelli, Chiara / Pucci, Carlotta / Battaglini, Matteo / Marino, Attilio / Ciofani, Gianni

    Advanced healthcare materials

    2019  Volume 9, Issue 3, Page(s) e1901589

    Abstract: ... and insufficient blood-brain barrier crossing efficiency. To overcome the limitations of antioxidant ... is proposed. In this review, after a brief discussion concerning the role of the blood-brain barrier ... Many central nervous system (CNS) diseases are still incurable and only symptomatic treatments are ...

    Abstract Many central nervous system (CNS) diseases are still incurable and only symptomatic treatments are available. Oxidative stress is suggested to be a common hallmark, being able to cause and exacerbate the neuronal cell dysfunctions at the basis of these pathologies, such as mitochondrial impairments, accumulation of misfolded proteins, cell membrane damages, and apoptosis induction. Several antioxidant compounds are tested as potential countermeasures for CNS disorders, but their efficacy is often hindered by the loss of antioxidant properties due to enzymatic degradation, low bioavailability, poor water solubility, and insufficient blood-brain barrier crossing efficiency. To overcome the limitations of antioxidant molecules, exploitation of nanostructures, either for their delivery or with inherent antioxidant properties, is proposed. In this review, after a brief discussion concerning the role of the blood-brain barrier in the CNS and the involvement of oxidative stress in some neurodegenerative diseases, the most interesting research concerning the use of nano-antioxidants is introduced and discussed, focusing on the synthesis procedures, functionalization strategies, in vitro and in vivo tests, and on recent clinical trials.
    MeSH term(s) Animals ; Antioxidants/pharmacokinetics ; Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Blood-Brain Barrier/drug effects ; Central Nervous System Diseases/drug therapy ; Central Nervous System Diseases/etiology ; Clinical Trials as Topic ; Drug Delivery Systems/methods ; Humans ; Nanostructures/administration & dosage ; Nanostructures/chemistry ; Neurodegenerative Diseases/drug therapy ; Oxidative Stress ; Reactive Oxygen Species/metabolism
    Chemical Substances Antioxidants ; Reactive Oxygen Species
    Language English
    Publishing date 2019-12-18
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2649576-4
    ISSN 2192-2659 ; 2192-2640
    ISSN (online) 2192-2659
    ISSN 2192-2640
    DOI 10.1002/adhm.201901589
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top